45 related articles for article (PubMed ID: 23361938)
1. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis.
Potenza RL; Armida M; Ferrante A; Pèzzola A; Matteucci A; Puopolo M; Popoli P
J Neurosci Res; 2013 Apr; 91(4):585-92. PubMed ID: 23361938
[TBL] [Abstract][Full Text] [Related]
2. Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death.
Rossi D
Prog Neurobiol; 2015 Jul; 130():86-120. PubMed ID: 25930681
[TBL] [Abstract][Full Text] [Related]
3. Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase.
Nascimento F; Pousinha PA; Correia AM; Gomes R; Sebastião AM; Ribeiro JA
PLoS One; 2014; 9(8):e104081. PubMed ID: 25093813
[TBL] [Abstract][Full Text] [Related]
4. Amyotrophic Lateral Sclerosis in Long-COVID Scenario and the Therapeutic Potential of the Purinergic System in Neuromodulation.
Leão Batista Simões J; Webler Eichler S; Raitz Siqueira ML; de Carvalho Braga G; Bagatini MD
Brain Sci; 2024 Feb; 14(2):. PubMed ID: 38391754
[TBL] [Abstract][Full Text] [Related]
5. Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine.
Rei N; Valente CA; Vaz SH; Farinha-Ferreira M; Ribeiro JA; Sebastião AM
PLoS One; 2022; 17(12):e0272104. PubMed ID: 36516126
[TBL] [Abstract][Full Text] [Related]
6. The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
Bassani D; Pavan M; Federico S; Spalluto G; Sturlese M; Moro S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562894
[TBL] [Abstract][Full Text] [Related]
7. The Pharmacological Potential of Adenosine A
Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.
Chang CP; Wu KC; Lin CY; Chern Y
J Biomed Sci; 2021 Oct; 28(1):70. PubMed ID: 34635103
[TBL] [Abstract][Full Text] [Related]
9. How Are Adenosine and Adenosine A
Mori A; Cross B; Uchida S; Kerrick Walker J; Ristuccia R
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440231
[TBL] [Abstract][Full Text] [Related]
10. Coffee and Tea Consumption Impact on Amyotrophic Lateral Sclerosis Progression: A Multicenter Cross-Sectional Study.
Cucovici A; Ivashynka A; Fontana A; Russo S; Mazzini L; Mandrioli J; Lisnic V; Muresanu DF; Leone MA
Front Neurol; 2021; 12():637939. PubMed ID: 34393966
[No Abstract] [Full Text] [Related]
11. Metabolic Aspects of Adenosine Functions in the Brain.
Garcia-Gil M; Camici M; Allegrini S; Pesi R; Tozzi MG
Front Pharmacol; 2021; 12():672182. PubMed ID: 34054547
[TBL] [Abstract][Full Text] [Related]
12. Modulating P1 Adenosine Receptors in Disease Progression of SOD1
Armida M; Matteucci A; Pèzzola A; Baqi Y; Müller CE; Popoli P; Potenza RL
Neurochem Res; 2019 May; 44(5):1037-1042. PubMed ID: 30756215
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases.
Herden L; Weissert R
Front Nutr; 2018; 5():133. PubMed ID: 30622948
[No Abstract] [Full Text] [Related]
14. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives.
Cieślak M; Roszek K; Wujak M
Purinergic Signal; 2019 Mar; 15(1):1-15. PubMed ID: 30430356
[TBL] [Abstract][Full Text] [Related]
15. Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions.
Ngo ST; Mi JD; Henderson RD; McCombe PA; Steyn FJ
Degener Neurol Neuromuscul Dis; 2017; 7():95-108. PubMed ID: 30050381
[TBL] [Abstract][Full Text] [Related]
16. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.
Sebastião AM; Rei N; Ribeiro JA
Front Pharmacol; 2018; 9():267. PubMed ID: 29713276
[TBL] [Abstract][Full Text] [Related]
17. Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.
Oliveira-Giacomelli Á; Naaldijk Y; Sardá-Arroyo L; Gonçalves MCB; Corrêa-Velloso J; Pillat MM; de Souza HDN; Ulrich H
Front Pharmacol; 2018; 9():325. PubMed ID: 29692728
[TBL] [Abstract][Full Text] [Related]
18. Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.
Fang X
Metab Brain Dis; 2018 Aug; 33(4):1031-1043. PubMed ID: 29681010
[TBL] [Abstract][Full Text] [Related]
19. The D2 Dopamine Receptor Interferes With the Protective Effect of the A
Lai CY; Liu YJ; Lai HL; Chen HM; Kuo HC; Liao YP; Chern Y
Front Neurosci; 2018; 12():187. PubMed ID: 29615863
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
